Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial

Lancet

Volumn 366, Issue 9501, 2005, Pages 1935-1944

  Nitz, Ulrike Anneliese ^a   Mohrmann, Svjetlana ^a   Fischer, Johannes ^a   Lindemann, Walter ^b   Berdel, Wolfgang E ^c   Jackisch, Christian ^c   Werner, Christoph ^d   Ziske, Carsten ^e   Kirchner, Hartmut ^f   Metzner, Bernd ^g   Souchon, Rainer ^h   Ruffert, Ute ⁱ   Schütt, Gerhart ^a   Pollmanns, Anke ^j   Schmoll, Hans Joachim ^k   Middecke, Constantin ^l   Baltzer, Jörg ^m   Schrader, Iris ^n,o   Wiebringhaus, Herrmann ^p   Ko, Yon ^q   Rösel, Siegfried ^r   Schwenzer, Thomas ^s   Wernet, Peter ^a   Hinke, Axel ^t   Bender, Hans Georg ^a   Frick, Markus ^a   more..

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Catholic Hospital   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d Evangelical Bethesda Johanniter Clinical Center   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f Siloah Clinic   (Germany)

^g City Hospital   (Germany)

^h Allgemeines Krankenhaus Hagen gem GmbH   (Germany)

ⁱ Institut für Blutzellanalyse und Therapie   (Germany)

^j Department of Gynaecology and Obstetrics   (Germany)

^k MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^l Lippe Hospital Lemgo   (Germany)

^m Department of Gynaecology and Obstetrics   (Germany)

ⁿ Medical Polyclinics University of Bonn ^*  (Germany)

^o Henrietten Hospital   (Germany)

^p St Barbara Klinik   (Germany)

^q UNIVERSITY OF BONN   (Germany)

^r Department of Oncology and Haematology   (Germany)

^s Department of Gynaecology and Obstetrics   (Germany)

^t WiSP Institute   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MESNA; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMATURIA; HUMAN; HUMAN CELL; HYPERPIGMENTATION; INFECTION; KIDNEY DYSFUNCTION; LEUKEMIA; LIVER TOXICITY; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; PAIN; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

EID: 28244478884     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67784-7     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
2. Roché H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. In: Proceedings of 27th Annual Breast Cancer Symposium, 2004, San Antonio, TX, USA: abstr 27.
3. Jones SE, Savin MA, Asmar L, et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/ cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). In: Grunberg SM, ed. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology, 2003, Chicago, IL, USA: abstr 59.
4. EP Mamounas, J Bryant, B Lembersky Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 J Clin Oncol 23 2005 3686 3696
5. M Martin, T Pienkowski, J Mackey Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2005 2302 2313
6. IC Henderson, DA Berry, GD Demtri Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 2003 976 983
7. AU Buzdar, SE Singletary, V Valero Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial Clin Cancer Res 8 2002 1073 1079
8. Gianni L, Baselga J, Eiermann W, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). In: Grunberg SM, ed. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology, 2005, Orlando, FL, USA: abstr 513.
9. Goldstein L, O'Neill A, Sparano J, et al. E2197: Phase III AT (doxorubucin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. In: Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology, 2005, Orlando, FL, USA: abstr 512.
10. W Hryniuk, MN Levine Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer J Clin Oncol 4 1986 1162 1170
11. WP Peters, M Ross, JJ Vredenburgh High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J Clin Oncol 11 1993 1132 1142
12. C Farquhar, R Basser, J Marjoribanks, A Lethaby High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer Cochrane Database Syst Rev 1 2003 CD003139
13. Peters WP, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC Ma 13. In: Perry M, ed. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology, 1999, Atlanta, GA, USA: abstr 2.
14. J Bergh, T Wiklund, B Erikstein Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial Lancet 356 2000 1384 1391
15. S Rodenhuis, M Bontenbal, LV Beex High-dose chemotherapy with hematopoetic stem-cell rescue for high risk breast cancer N Engl J Med 349 2003 7 16
16. RC Leonard, M Lind, C Twelves Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial J Natl Cancer Inst 96 2004 1076 1083
17. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+). In: Grunberg SM, ed. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology, 2001, San Francisco, CA, USA: abstr 80.
18. Roché H, Pouillart P, Meyer N, et al. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7)breast cancer patients: the Pegase 01 Trial. In: Grunberg SM, ed. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology, 2001, San Francisco, CA, USA: abstr 102.
19. WP Peters, GL Rosner, JJ Vredenburgh Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13 J Clin Oncol 23 2005 2191 2200
20. G Bonadonna, M Zambetti, P Valagussa Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes JAMA 273 1995 542 547
21. Poole CJ, Earl HM, Dunn JA, et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. In: Grunberg SM, ed. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology, 2003, Chicago, IL, USA: abstr 13.
22. ML Citron, DA Berry, C Cirrincione Randomized trial of dose-dense conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C 9741/ Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439
23. AR Zander, N Kröger, C Schmoor High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial J Clin Oncol 22 2004 2273 2283
24. BA Teicher, CA Cucchi, JB Lee, JL Flatow, A Rosowsky, Frei E III Alkylating agents: in vitro studies of cross-resistance patterns in human tumor cell lines Cancer Res 46 1986 4379 4383
25. MJ Kennedy, RA Beveridge, SD Rowley, GB Gordon, MD Abeloff, NE Davidson High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose intense induction as initial therapy for metastatic breast cancer J Natl Cancer Inst 83 1991 920 926
26. MS Tallman, R Gray, NJ Robert Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med 349 2003 17 26
27. J Crown, C Wassherheit, T Hakes Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells J Natl Cancer Inst 84 1992 1935 1936
28. J Crown, L Norton Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer Ann Oncol 6 suppl 4 1995 21 26
29. M Attal, JL Harousseau, T Facon Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2003 2495 2502
30. Crown JP, Leyvraz S, Verrill M, et al. Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: mature results of the IBDIS-I. In: Grunberg SM, ed. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology, 2004: New Orleans, LA, USA: abstr 631.
31. Basser R, O'Neill A, Martinelli G, et al. Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy versus standard dose chemotherapy in women with high-risk stage 2 or 3 breast cancer: first results from IBSG Trial 15-95. In: Grunberg SM, ed. 39th Annual Meeting of the American Society of Clinical Oncology, 2003, Chicago, IL, USA: abstr 20.